.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a typical consequence of 11 months, patients with metastatic stomach cysts who got biomarker-matched therapies based on flowing tumor DNA profiling showed a greater professional benefit than those acquiring unrivaled therapy.